Motoo Nagane
YOU?
Author Swipe
View article: Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas Open
Background Gliomas are primary brain tumors arising from glial cells. WHO grade 2 gliomas are initially managed with surgery for diagnosis and tumor reduction. However, complete resection is difficult due to their infiltrative growth into …
View article: CTNI-16. PATIENT BACKGROUNDS ASSOCIATED WITH THE PROLONGED EFFECTIVENESS OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: RESULTS FROM THE ROSETTA STUDY
CTNI-16. PATIENT BACKGROUNDS ASSOCIATED WITH THE PROLONGED EFFECTIVENESS OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: RESULTS FROM THE ROSETTA STUDY Open
BACKGROUND An interim analysis of ROSETTA (jRCT1021230006), a cohort study conducted in Japan, indicated favorable effectiveness and manageable safety of tirabrutinib for relapsed or refractory primary central nervous system lymphoma (r/rP…
View article: CTNI-75. SAFETY AND EFFICACY OF METFORMIN AND TEMOZOLOMIDE TARGETING CANCER STEM CELLS FOR NEWLY DIAGNOSED GLIOBLASTOMA
CTNI-75. SAFETY AND EFFICACY OF METFORMIN AND TEMOZOLOMIDE TARGETING CANCER STEM CELLS FOR NEWLY DIAGNOSED GLIOBLASTOMA Open
BACKGROUND Metformin (MF), an antidiabetic drug, induces the differentiation of stem-like glioma-initiating cells and suppresses tumor formation via AMPK-FOXO3 activation. Based on this theory, we conducted a phase I/II study to evaluate t…
View article: PTHP-07. Clinical and Molecular Characteristics of Japanese Medulloblastoma, SHH-Activated
PTHP-07. Clinical and Molecular Characteristics of Japanese Medulloblastoma, SHH-Activated Open
BACKGROUND Medulloblastomas (MBs) are categorized into four molecular subgroups: WNT, SHH, Group 3, and Group 4, as defined by the WHO classification. SHH-activated MB (SHH-MB) is more common in infants and adults, and genetically characte…
View article: Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma
Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma Open
What is this summary about?
View article: Aspiration prevention surgeries for adult patients with brainstem malignant gliomas: illustrative cases
Aspiration prevention surgeries for adult patients with brainstem malignant gliomas: illustrative cases Open
BACKGROUND Adult patients with brainstem gliomas have a poor prognosis, with a median survival of approximately 1 year. Although patients often remain conscious until the end of life, lesions affecting the medulla oblongata can cause sever…
View article: Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans
Retraction of Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans Open
View article: Posterior Reversible Encephalopathy Syndrome Arising from Simultaneous Cranioplasty and Ventriculoperitoneal Shunting: A Case Report
Posterior Reversible Encephalopathy Syndrome Arising from Simultaneous Cranioplasty and Ventriculoperitoneal Shunting: A Case Report Open
Posterior reversible encephalopathy syndrome is a well-known condition that causes reversible vasogenic edema, mainly in the occipital lobe. However, no guideline for its diagnosis or treatment has been established to date. While many atyp…
View article: EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis Open
View article: 10048- COT-5 DEVELOPMENT OF A DIAGNOSTIC MODEL FOR GLIOMAS USING SERUM MICRO RNA
10048- COT-5 DEVELOPMENT OF A DIAGNOSTIC MODEL FOR GLIOMAS USING SERUM MICRO RNA Open
BACKGROUND MicroRNAs (miRNAs) are non-coding RNAs consisting of approximately 20 base pairs. Several studies have reported the usefulness of serum miRNAs in the diagnosis of gliomas. However, the results differ among studies, and reproduci…
View article: 10064- ML-2 CLINICAL CHARACTERISTICS OF NON-COMPLETE RESPONDERS TO MTX-BASED INDUCTION THERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA
10064- ML-2 CLINICAL CHARACTERISTICS OF NON-COMPLETE RESPONDERS TO MTX-BASED INDUCTION THERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA Open
BACKGROUND The standard care for primary CNS lymphoma (PCNSL) is high-dose methotrexate (HD-MTX)-based induction therapy including R-MPV followed by consolidation therapy with a high CR/CRu rate. However, non-CR (refractory) patients may f…
View article: 10076- MPC-8 MOLECULAR DIAGNOSIS OF MEDULLOBLASTOMA: CHARACTERISTICS OF JAPANESE CASES AND DIAGNOSTIC METHODS FOR WNT MBS.
10076- MPC-8 MOLECULAR DIAGNOSIS OF MEDULLOBLASTOMA: CHARACTERISTICS OF JAPANESE CASES AND DIAGNOSTIC METHODS FOR WNT MBS. Open
BACKGROUND Medulloblastomas have been subdivided into pathological morphological groups, but since 2012, consensus has been reached on four different molecular subgroups, including wingless (WNT)-activated, sonic hedgehog (SHH)-activated, …
View article: 10211- GEN-12 IDENTIFICATION OF PROGNOSIS-RELATED METHYLATION PROFILES AND METHYLATION BIOMARKERS IN IDH-WILD-TYPE GLIOBLASTOMA
10211- GEN-12 IDENTIFICATION OF PROGNOSIS-RELATED METHYLATION PROFILES AND METHYLATION BIOMARKERS IN IDH-WILD-TYPE GLIOBLASTOMA Open
BACKGROUND Genome-wide DNA methylation analysis is currently available and is used to diagnose brain tumors. Although MGMT promoter hypermethylation is a strong biomarker in glioblastoma (GBM), there are few reports of DNA methylation prof…
View article: Association between microenvironment‐related genes and prognosis of primary central nervous system lymphoma
Association between microenvironment‐related genes and prognosis of primary central nervous system lymphoma Open
Background Primary central nervous system lymphoma (PCNSL) is a rare lymphoid malignancy. Systemic profiling of the PCNSL tumor microenvironment (TME) was previously conducted through gene expression analysis. We investigated the prognosti…
View article: Could video game-based physical rehabilitation substitute for conventional physiotherapy in patients with glioma? A proof-of-concept study
Could video game-based physical rehabilitation substitute for conventional physiotherapy in patients with glioma? A proof-of-concept study Open
Purpose The present study investigated the clinical feasibility of replacing a part of conventional physiotherapy (PT) with Nintendo Wii® for the recovery of motor function and activities of daily living (ADL) in patients with glioma. Meth…
View article: Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group Open
Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved. Methods We …
View article: GCT-15. CLINICAL AND MOLECULAR CHARACTERIZATION OF INFANTILE CENTRAL NERVOUS SYSTEM GERM CELL TUMORS
GCT-15. CLINICAL AND MOLECULAR CHARACTERIZATION OF INFANTILE CENTRAL NERVOUS SYSTEM GERM CELL TUMORS Open
BACKGROUND The management of infantile central nervous system germ cell tumors (CNS-GCTs) presents unique challenges, including variable clinical presentations such as tumor size and propensity for hemorrhage. Moreover, data on the clinica…
View article: MDB-16. CLINICAL AND MOLECULAR CHARACTERISTICS OF JAPANESE MEDULLOBLASTOMA, WNT-ACTIVATED
MDB-16. CLINICAL AND MOLECULAR CHARACTERISTICS OF JAPANESE MEDULLOBLASTOMA, WNT-ACTIVATED Open
BACKGROUND Medulloblastomas are at least classified into four core subgroups, including WNT-activated, SHH-activated, group 3 and group 4. These molecular subgroups have been introduced in the latest WHO classification, which has become fu…
View article: Preface for Brain Tumor Pathology vol.41 issue 2
Preface for Brain Tumor Pathology vol.41 issue 2 Open
View article: Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma Open
Background The ONO-4059-02 phase 1/2 study showed favorable efficacy and acceptable safety profile of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, for relapsed/refractory primary central nervous system lymphoma (PC…
View article: Treatment Strategies for Recurrent Glioblastoma
Treatment Strategies for Recurrent Glioblastoma Open
View article: 10259-NQPC-9 CONTROVERSY ON INVASIVE AIRWAY MANAGEMENT IN PATIENTS WITH BRAIN STEM MALIGNANT GLIOMA.
10259-NQPC-9 CONTROVERSY ON INVASIVE AIRWAY MANAGEMENT IN PATIENTS WITH BRAIN STEM MALIGNANT GLIOMA. Open
INTRODUCTION The prognosis for patients with malignant gliomas of the brainstem is poor. As the tumor progresses into the medulla oblongata, the lower cranial nerves are affected, resulting in dysphagia and eventually respiratory paralysis…
View article: 10221-ML-11 A CASE OF PRIMARY CENTRAL NERVOUS SYSTEM ADULT T CELL LEUKEMIA
10221-ML-11 A CASE OF PRIMARY CENTRAL NERVOUS SYSTEM ADULT T CELL LEUKEMIA Open
Adult T cell leukemia (ATL) manifesting only in the central nervous system (CNS) at presentation is rare. We present a case of primary CNS ATL. 54 year old male presenting with multiple enhanced lesions in the cerebrum went under biopsy an…
View article: CTNI-68. PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR TARGETING GLIOBLASTOMA CANCER STEM CELLS
CTNI-68. PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR TARGETING GLIOBLASTOMA CANCER STEM CELLS Open
BACKGROUND Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis. One strategy for overcoming resistance is developing a new therapy targeting the cancer stem/initiating cells. We have shown that the antidiabetic drug…
View article: CTNI-81. REAL-WORLD TREATMENT RESULTS OF RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATED BY MEDICAL THERAPIES
CTNI-81. REAL-WORLD TREATMENT RESULTS OF RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATED BY MEDICAL THERAPIES Open
Recurrence of primary central nervous system lymphoma (PCNSL) is a condition which often leads to morbidity and mortality. Consensus regarding the optimal treatment regimen for relapsed PCNSL has not been achieved due to the rarity of the …
View article: Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study
Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study Open
View article: Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors
Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors Open
We have previously reported that 12p gain may predict the presence of malignant components and poor prognosis for CNS germ cell tumor (GCT). Recently, 3p25.3 gain was identified as an independent predictor of poor prognosis for testicular …
View article: The role of nonlinear dimension reduction of genome‐wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH‐wildtype
The role of nonlinear dimension reduction of genome‐wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH‐wildtype Open
View article: Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma Open
Supplementary Table Legends and Information, Supplementary Figures 1-11
View article: Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma
Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma Open
Supplementary Table Legends and Information, Supplementary Figures 1-11